Glaukos Corporation
Aliso Viejo, California, United States · Biotechnology, Health Care, Medical
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that focuses on developing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company aims to provide novel, non-invasive treatments designed to improve patient comfort and recovery times. Their product, Epioxa™, is part of their iLink therapy line, which utilizes bio-ac
Key facts
- Headquarters
- Aliso Viejo, California, United States
- Employees
- 871
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (GKOS)
- Website
- glaukos.com
- Company page
Recent activity at Glaukos Corporation
- : SEC 8-K (7.01):
- : SEC 8-K (7.01):
- : SEC 8-K (7.01):
- : SEC 8-K (7.01):
- : SEC 8-K (7.01):
- : GLAUKOS Corp acquires Mobius Therapeutics for $12.4M
- : SEC 8-K (7.01):
- : SEC 8-K (7.01): The Company, Glaukos Corporation, is intending to present an Investor Presentation to investors and other stakeholders, with materials attached as Exhibit 99.2 to this Current Report. This presentation will be accessible on their investor website, indicating ongoing communication and engagement with the investment community. The filing details that the information should not be considered filed for purposes of the Exchange Act unless explicitly referenced. The date of the filing is January 13, 2026, and it highlights the company's efforts to inform stakeholders and enhance their visibility in the market.
- : SEC 8-K (2.02): On January 13, 2026, Glaukos Corporation announced preliminary, unaudited net sales results for the fourth quarter and fiscal year ended December 31, 2025. The release indicates sales details that will provide insights into the company's financial health and performance over the past year, which may impact future investment decisions. This quarter's results are particularly critical as they give stakeholders a view of the company's trajectory and operational efficiency. The specific financial figures will be presented in the associated press release, which serves as a key update for investors and market analysts regarding Glaukos's ongoing business performance.
- : SEC 8-K (7.01):
Leadership
- Joseph Gilliam, Chief Executive Officer
- Simon Eade, Head of Human Resources
- Andrea Perez, Human Resources Manager
- Michele Allegretto, Chief Human Resources and Organizational Development Executive
- Tim Daly, Sr. Manager, Finance
- Tiffany Dam, Finance Manager
- Max Shaffer, Electrical Engineer
- Robert B., Principal Engineer
- Christopher Torres, Information Technology System Engineer
- Lisa S., Marketing Leader
- Melissa Chaves, Sr. Director, Global Marketing
- Lauren Mcbride, Marketing Manager
Verified email and direct lines for Glaukos Corporation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Glaukos Corporation files 6 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Glaukos Corporation in the news
- Glaukos Announces Participation in Wells Fargo Healthcare Conference - Business Wire (Aug 19, 2026)
- Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 - Business Wire (Jul 08, 2026)
- US FDA approves Glaukos' new eye therapy - Reuters (Oct 20, 2025)
- Glaukos' Epioxa maintains corneal flattening and visual gains through 3 years in keratoconus - Ophthalmology Times (Oct 08, 2026)
- Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma - MedTech Dive (Dec 15, 2023)
- Glaukos receives FDA approval for Epioxa topical therapy for keratoconus - Ophthalmology Times (Oct 20, 2025)
- Glaukos Announces Second Quarter 2026 Financial Results - Business Wire (Jul 29, 2026)
- Glaukos’ Epioxa for keratoconus receives permanent J-code effective July 1, 2026 - Ophthalmology Times (Apr 18, 2026)
Companies similar to Glaukos Corporation
- Vectura Group Limited · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Radius · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Ryvu Therapeutics · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- InnoCare Pharma · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Glaukos Corporation: questions and answers
What does Glaukos Corporation do?
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that focuses on developing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company aims to provide novel, non-invasive treatments designed to improve patient comfort and recovery times. Their product, Epioxa™, is part of their iLink therapy line, which utilizes bio-ac
Where is Glaukos Corporation headquartered?
Glaukos Corporation is headquartered in Aliso Viejo, California, United States.
How many employees does Glaukos Corporation have?
Glaukos Corporation has about 871 employees.
Who leads Glaukos Corporation?
Joseph Gilliam is a Chief Executive Officer at Glaukos Corporation.
What is the latest news on Glaukos Corporation?
On Aug 03, 2026, SEC 8-K (7.01):
Is Glaukos Corporation a public company?
Yes. Glaukos Corporation is publicly traded under the ticker GKOS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy